ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
N Perico, P Ruggenenti, G Remuzzi - Current opinion in pharmacology, 2017 - Elsevier
Highlights•Current strategies to prevent or revert renal disease progression in proteinuric
nephropathies focus on reduction of abnormal protein trafficking through the glomerular
capillary wall.•Blockade of the renin-angiotensin system (RAS) by means of ACE inhibitors
and/or ARBs is the most effective treatment to slow renal disease progression.•Combination
therapy with ACEi and ARBs inhibits the RAS more efficiently than does each agent alone
through an addictive effect, but requires close monitoring of patients.•Novel treatment …
nephropathies focus on reduction of abnormal protein trafficking through the glomerular
capillary wall.•Blockade of the renin-angiotensin system (RAS) by means of ACE inhibitors
and/or ARBs is the most effective treatment to slow renal disease progression.•Combination
therapy with ACEi and ARBs inhibits the RAS more efficiently than does each agent alone
through an addictive effect, but requires close monitoring of patients.•Novel treatment …